Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
Consult your doctor
D.SamsudinS
Delara Tavakoli, M.D
AOD-9604: Direct Lipolysis Theory AOD-9604 is a modified C-terminal fragment of human growth hormone, designed to isolate GH's fat-metabolizing properties: Lipolysis Activation: Theorized to stimulate fat breakdown through beta-3 adrenergic receptor pathways No IGF-1 Stimulation: Unlike full GH, AOD-9604 does not elevate insulin-like growth factor 1 Non-diabetogenic: Does not impair glucose metabolism or insulin sensitivity No Anabolic Effects: Does not promote muscle or organ growth Semaglutide: Central Regulation Theory Semaglutide achieves weight loss through systemic metabolic regulation: Hypothalamic Appetite Control: GLP-1 receptors in the brain reduce hunger and food-seeking behavior Gastric Emptying: Slowed stomach emptying promotes early satiety Insulin Optimization: Glucose-dependent insulin secretion improves metabolic efficiency Reward Pathway Modulation: Reduced hedonic eating and food reward responses The fundamental difference: AOD-9604 attempts to "burn" existing fat directly, while Semaglutide reduces caloric intake through appetite and satiety mechanisms, creating an energy deficit that leads to fat loss
10.1111/ejn.14335 Eur
A controlled trial in 80 patients with known heart disease already using anti-arrhythmic drugs found adding 1 gram of omega-3 fatty acids daily for six months further reduced the number of ventricular arrhythmia events (Gavva 2012)
US$ 21.24
US$ 21.58
US$ 23.42
US$ 26.78
US$ 20.55
US$ 21.36